Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein

Michael Ohh, Yuichiro Takagi, Teijiro Aso, Charles E. Stebbins, Nikola P. Pavletich, Bert Zbar, Ronald C. Conaway, Joan Weliky Conaway, William G. Kaelin

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The von Hippel-Lindau tumor suppressor protein (pVHL) negatively regulates hypoxia-inducible mRNAs such as the mRNA encoding vascular endothelial growth factor (VEGF). This activity has been linked to its ability to form multimeric complexes that contain elongin C, elongin B, and Cul2. To understand this process in greater detail, we performed a series of in vitro binding assays using pVHL, elongin B, and elongin C variants as well as synthetic peptide competitors derived from pVHL or elongin C. A subdomain of elongin C (residues 17-50) was necessary and sufficient for detectable binding to elongin B. In contrast, elongin B residues required for binding to elongin C were not confined to a discrete colinear domain. We found that the pVHL (residues 157-171) is necessary and sufficient for binding to elongin C in vitro and is frequently mutated in families with VHL disease. These mutations preferentially involve residues that directly bind to elongin C and/or alter the conformation of pVHL such that binding to elongin C is at least partially diminished. These results are consistent with the view that diminished binding of pVHL to the elongins plays a causal role in VHL disease.

Original languageEnglish (US)
Pages (from-to)1583-1591
Number of pages9
JournalJournal of Clinical Investigation
Volume104
Issue number11
StatePublished - Dec 1999
Externally publishedYes

Fingerprint

Peptides
Proteins
elongin
Von Hippel-Lindau Tumor Suppressor Protein
Messenger RNA
Vascular Endothelial Growth Factor A
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ohh, M., Takagi, Y., Aso, T., Stebbins, C. E., Pavletich, N. P., Zbar, B., ... Kaelin, W. G. (1999). Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. Journal of Clinical Investigation, 104(11), 1583-1591.

Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. / Ohh, Michael; Takagi, Yuichiro; Aso, Teijiro; Stebbins, Charles E.; Pavletich, Nikola P.; Zbar, Bert; Conaway, Ronald C.; Conaway, Joan Weliky; Kaelin, William G.

In: Journal of Clinical Investigation, Vol. 104, No. 11, 12.1999, p. 1583-1591.

Research output: Contribution to journalArticle

Ohh, M, Takagi, Y, Aso, T, Stebbins, CE, Pavletich, NP, Zbar, B, Conaway, RC, Conaway, JW & Kaelin, WG 1999, 'Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein', Journal of Clinical Investigation, vol. 104, no. 11, pp. 1583-1591.
Ohh, Michael ; Takagi, Yuichiro ; Aso, Teijiro ; Stebbins, Charles E. ; Pavletich, Nikola P. ; Zbar, Bert ; Conaway, Ronald C. ; Conaway, Joan Weliky ; Kaelin, William G. / Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. In: Journal of Clinical Investigation. 1999 ; Vol. 104, No. 11. pp. 1583-1591.
@article{413d2797e8b9439f857517ad507ba721,
title = "Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein",
abstract = "The von Hippel-Lindau tumor suppressor protein (pVHL) negatively regulates hypoxia-inducible mRNAs such as the mRNA encoding vascular endothelial growth factor (VEGF). This activity has been linked to its ability to form multimeric complexes that contain elongin C, elongin B, and Cul2. To understand this process in greater detail, we performed a series of in vitro binding assays using pVHL, elongin B, and elongin C variants as well as synthetic peptide competitors derived from pVHL or elongin C. A subdomain of elongin C (residues 17-50) was necessary and sufficient for detectable binding to elongin B. In contrast, elongin B residues required for binding to elongin C were not confined to a discrete colinear domain. We found that the pVHL (residues 157-171) is necessary and sufficient for binding to elongin C in vitro and is frequently mutated in families with VHL disease. These mutations preferentially involve residues that directly bind to elongin C and/or alter the conformation of pVHL such that binding to elongin C is at least partially diminished. These results are consistent with the view that diminished binding of pVHL to the elongins plays a causal role in VHL disease.",
author = "Michael Ohh and Yuichiro Takagi and Teijiro Aso and Stebbins, {Charles E.} and Pavletich, {Nikola P.} and Bert Zbar and Conaway, {Ronald C.} and Conaway, {Joan Weliky} and Kaelin, {William G.}",
year = "1999",
month = "12",
language = "English (US)",
volume = "104",
pages = "1583--1591",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein

AU - Ohh, Michael

AU - Takagi, Yuichiro

AU - Aso, Teijiro

AU - Stebbins, Charles E.

AU - Pavletich, Nikola P.

AU - Zbar, Bert

AU - Conaway, Ronald C.

AU - Conaway, Joan Weliky

AU - Kaelin, William G.

PY - 1999/12

Y1 - 1999/12

N2 - The von Hippel-Lindau tumor suppressor protein (pVHL) negatively regulates hypoxia-inducible mRNAs such as the mRNA encoding vascular endothelial growth factor (VEGF). This activity has been linked to its ability to form multimeric complexes that contain elongin C, elongin B, and Cul2. To understand this process in greater detail, we performed a series of in vitro binding assays using pVHL, elongin B, and elongin C variants as well as synthetic peptide competitors derived from pVHL or elongin C. A subdomain of elongin C (residues 17-50) was necessary and sufficient for detectable binding to elongin B. In contrast, elongin B residues required for binding to elongin C were not confined to a discrete colinear domain. We found that the pVHL (residues 157-171) is necessary and sufficient for binding to elongin C in vitro and is frequently mutated in families with VHL disease. These mutations preferentially involve residues that directly bind to elongin C and/or alter the conformation of pVHL such that binding to elongin C is at least partially diminished. These results are consistent with the view that diminished binding of pVHL to the elongins plays a causal role in VHL disease.

AB - The von Hippel-Lindau tumor suppressor protein (pVHL) negatively regulates hypoxia-inducible mRNAs such as the mRNA encoding vascular endothelial growth factor (VEGF). This activity has been linked to its ability to form multimeric complexes that contain elongin C, elongin B, and Cul2. To understand this process in greater detail, we performed a series of in vitro binding assays using pVHL, elongin B, and elongin C variants as well as synthetic peptide competitors derived from pVHL or elongin C. A subdomain of elongin C (residues 17-50) was necessary and sufficient for detectable binding to elongin B. In contrast, elongin B residues required for binding to elongin C were not confined to a discrete colinear domain. We found that the pVHL (residues 157-171) is necessary and sufficient for binding to elongin C in vitro and is frequently mutated in families with VHL disease. These mutations preferentially involve residues that directly bind to elongin C and/or alter the conformation of pVHL such that binding to elongin C is at least partially diminished. These results are consistent with the view that diminished binding of pVHL to the elongins plays a causal role in VHL disease.

UR - http://www.scopus.com/inward/record.url?scp=0033404668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033404668&partnerID=8YFLogxK

M3 - Article

C2 - 10587522

AN - SCOPUS:0033404668

VL - 104

SP - 1583

EP - 1591

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -